OVERVIEW

Saturday Morning Coffee with Experts in NASH: What Is The Update? is organized by CME Outfitters, LLC.

Premiere Date: Tuesday, November 10, 2020
Credit Expiration Date: Wednesday, November 10, 2021

Accreditation:
CME Credit (Physicians):
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs).

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

This activity offers CE credit for:
• Physicians (CME)
• Nurses (CNE)
• Pharmacists (ACPE)
• ABIM (MOC)
• Other

Statement of Need
Non-alcoholic steatohepatitis (NASH) is a severe and potentially life-threatening form of non-alcoholic fatty liver disease (NAFLD) that has emerged as a major health and societal burden in the United States. Of the estimated one in four individuals who have NAFLD, one in five has NASH, and although the pathogenesis of NAFLD and NASH have not been fully elucidated, it is a result of several pathways that may lead to advanced fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and death.

This CME Outfitters enduring material features a renowned panel of experts highlighting the underlying mechanisms of NASH via innovative augmented reality (AR) animations and presenting real-world case scenarios to share clinical insights on how to choose appropriate non-invasive diagnostic modalities, as well as translate latest data on emerging targeted therapies and their implications for clinical practice.

Learning Objectives
At the end of this CE activity, participants should be able to:
• Summarize the epidemiology of NAFLD and NASH and the factors driving the progression to advanced fibrosis.
• Determine candidates for liver biopsy versus noninvasive modalities for the staging of fibrosis in NASH.
• Evaluate the clinical significance of the latest clinical data on emerging targeted therapies for NASH.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Summarize the epidemiology of NAFLD and NASH and the factors driving the progression to advanced fibrosis.
• Identify candidates for liver biopsy versus noninvasive modalities for the staging of fibrosis in NASH.
• Evaluate the clinical significance of the latest clinical data on emerging targeted therapies for NASH.